18 ms·
I personally worked on developing the Investigative Brochure for procedure in preparation for the Phase 3 clinical trials at MAPS. The concerns regarding neurot
by ohbleek 9y ago
I personally worked on developing the Investigative Brochure for procedure in preparation for the Phase 3 clinical trials at MAPS. The concerns regarding neurotoxicity are mitigated through dosage and low frequency. The ideal treatment plan would only include one session with a therapist in which the patient is given a dosage of MDMA, over a six month period. During that session it's possible for the patient to receive a supplemental dosage dependent on the needs of the patient and the recommendations of the therapist. This can be adjusted and in previous trials some patients have had 2 MDMA-assisted sessions over 6 months but it is not common so far and other options are being considered.
- fitzroy 9y agoCan you comment at all about how the MDMA therapy session is conducted and/or structured, compared to a normal 50 minute session?
- catshirt 9y agoRick Doblin, founder of MAPS, talks a bit about this in his interview with Duncan Trussel: http://www.duncantrussell.com/episodes/2016/7/18/rick-doblin http://www.duncantrussell.com/episodes/2016/7/18/rick-doblin (i'd imagine this information is available elsewhere, this is just the instance i happened to come across myself...)
- anythingnonidin 9y agoRead: https://rollsafe.org/mdma-therapy/ https://rollsafe.org/mdma-therapy/